In a significant advancement for Alzheimer’s care, Health Canada has granted approval for Donanemab, a new medication designed to slow the progression of the disease. Manufactured by Eli Lilly and marketed under the brand name Kisunla, this drug received its green light on Monday, marking a pivotal moment for those affected by this debilitating condition. This approval follows the earlier endorsement of Lecanemab, known commercially as Leqembi, in October 2025, making Donanemab the second drug of its kind to gain approval in Canada.
Understanding Donanemab’s Mechanism
Similar to Lecanemab, Donanemab targets amyloid proteins—sticky substances that accumulate in the brains of individuals with Alzheimer’s, often leading to significant memory and cognitive challenges. While the newly approved medication is not a cure, clinical trials have indicated its potential to decelerate cognitive decline in certain patients during the early stages of Alzheimer’s. The Alzheimer Society of Canada emphasised that preliminary results showed promise in enhancing memory, thinking, and daily functioning for some individuals.
In trials, patients treated with Kisunla demonstrated a unique ability to discontinue the drug once amyloid plaques had been effectively cleared from their systems. Some participants were able to cease treatment after just six months, while nearly half stopped after one year. This flexibility offers hope, particularly for those in the initial phases of the disease, highlighting the drug’s potential to improve quality of life.
Clinical Trial Outcomes
The clinical data surrounding Donanemab is encouraging. Over an 18-month period, participants experiencing less advanced symptoms exhibited a remarkable 35 per cent reduction in decline on the integrated Alzheimer’s Disease Rating Scale (iADRS), which evaluates cognitive and daily living skills. For the broader participant group, the drug demonstrated an overall 22 per cent slowing of disease progression.
Christina Scicluna, CEO of the Alzheimer Society of Canada, hailed the approval as a “hopeful milestone” for individuals living with early Alzheimer’s and their caregivers. She stressed the importance of ongoing research and advocacy efforts to ensure that patients have access to innovative treatments and necessary support systems.
Limitations and Future Considerations
Despite its promise, Health Canada has placed restrictions on Donanemab’s use, limiting it to adults who do not possess the APOE4 gene variant. This genetic marker, present in approximately one-fifth of the global population, is known to heighten the risk of developing dementia.
Additionally, potential side effects, such as amyloid-related imaging abnormalities (ARIA)—which can manifest as temporary brain swelling—have been noted by Eli Lilly. As the Canadian Drug Agency prepares to evaluate whether Donanemab will be funded by provincial and territorial drug plans, the Alzheimer Society of Canada is advocating for public coverage. However, they caution that the process for new medicines to gain public funding can often take up to two years post-approval.
The Path Ahead for Patients
For those with private insurance or extended health benefits, access to Donanemab may arrive more swiftly, alleviating some of the pressures faced by early-stage Alzheimer’s patients and their families. Experts like Dr. Sharon Cohen, a neurologist and medical director at the Toronto Memory Program, have highlighted the importance of this medication in helping patients maintain their independence and manage their daily lives.
“Changing the downward trajectory of Alzheimer’s disease is crucial,” Dr. Cohen remarked. “Individuals in the early stages of the disease often lead fulfilling lives but are apprehensive about the future. Donanemab offers them a chance to potentially prolong that independence.”
Why it Matters
The approval of Donanemab is more than just a medical breakthrough; it represents a beacon of hope for countless Canadians grappling with Alzheimer’s disease. As the healthcare landscape evolves, it is imperative that we continue to advocate for access to new treatments and the necessary support structures. This development underscores the significance of research and the collective efforts of advocacy groups, healthcare professionals, and policymakers in navigating the complexities of Alzheimer’s care. Ensuring that patients can access innovative therapies like Donanemab will be crucial in enhancing their quality of life and providing support to families during one of life’s most challenging journeys.
